BZ019

BIOLOGICAL3 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Shanghai Cell Therapy Group Co.,Ltd, Shanghai Mengchao Cancer Hospital

Conditions

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLarge B-cell LymphomaPrimary Mediastinal Large B Cell LymphomaTransformed Lymphoma

Phase 1

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

CompletedNCT04067414

Institute of Hematology & Blood Diseases Hospital, ChinaDiffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma +1

Start: 2018-06-08End: 2021-06-04Updated: 2026-02-11

Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

Shanghai Cell Therapy Group Co.,LtdLarge B-cell Lymphoma

Start: 2019-11-19End: 2022-12-31Target: 21Updated: 2020-01-31

Phase 2

Study of Efficacy of BZ019 in Large B-cell Lymphoma

Shanghai Mengchao Cancer HospitalLarge B-cell Lymphoma

Start: 2021-06-04End: 2023-01-31Target: 36Updated: 2022-07-25

Related Papers

Rapid response in relapsed follicular lymphoma with massive chylous ascites to anti-CD19 CAR T therapy using Piggy Bac: A case report

Frontiers in Immunology2022-12-013 citations